Motus GI Holdings, Inc. (MOTS): Price and Financial Metrics
MOTS Stock Summary
- With a market capitalization of $45,065,181, Motus GI Holdings Inc has a greater market value than just 8.76% of US stocks.
- The capital turnover (annual revenue relative to shareholder's equity) for MOTS is 0.01 -- better than merely 9.11% of US stocks.
- MOTS's price/sales ratio is 459.85; that's higher than the P/S ratio of 98.53% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Motus GI Holdings Inc are OCX, FUV, SMAR, EPAY, and DOMO.
- MOTS's SEC filings can be seen here. And to visit Motus GI Holdings Inc's official web site, go to www.motusgi.com.
MOTS Stock Price Chart Interactive Chart >
MOTS Price/Volume Stats
|Current price||$0.90||52-week high||$2.74|
|Prev. close||$0.96||52-week low||$0.62|
|Day high||$0.98||Avg. volume||3,420,464|
|50-day MA||$1.42||Dividend yield||N/A|
|200-day MA||$1.15||Market Cap||41.87M|
Motus GI Holdings, Inc. (MOTS) Company Bio
Motus GI Holdings, Inc., a development stage company, engages in developing single-use medical device systems in the United States. It is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The company is based in Tirat Carmel, Israel.
MOTS Latest News Stream
|Loading, please wait...|
MOTS Latest Social Stream
View Full MOTS Social Stream
Latest MOTS News From Around the Web
Below are the latest news stories about Motus GI Holdings Inc that investors may wish to consider to help them evaluate MOTS as an investment opportunity.
Motus GI Holdings Inc (NASDAQ: MOTS ) has submitted a 510(k) application to the FDA for … Full story available on Benzinga.com
FORT LAUDERDALE, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System that is compatible with gastroscopes used during upper gastrointestinal (GI) endoscopy procedures to remove blood, blood clots and debris in order to provide a clear field-of-view for the endoscopist. The device is designed to integrate with therapeutic gastroscopes to enable safe and rapid cleansing during the procedure, while prese...
Motus GI Holdings, Inc. (MTS) Q4 2020 Earnings Conference Call March 16, 2021 04:30 p.m. ET Company Representatives Tim Moran - Chief Executive Officer Andy Taylor - Chief Financial Officer Mark Pomeranz - President, Chief Operating Officer Garth Russell - LifeSci Advisors Conference Call Participants Drew Stafford - Piper Sandler...
FXNEWS24 |Motus GI Holdings, Inc. (MOTS) Studies This autumn Loss, Lags Income Estimates | UK Forex Reviews
Motus GI Holdings, Inc. (MOTS) Studies This autumn Loss, Lags Income Estimates | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0.00% and -61.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MOTS Price Returns
Continue Researching MOTSWant to see what other sources are saying about Motus GI Holdings Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!